10-K: Creative Medical Technology Holdings Reports 2024 Results, Highlights Clinical Advancements

Creative Medical Technology Holdings reports its financial results for the year ended December 31, 2024, and provides updates on its clinical programs and pipeline development.

Summary

• Creative Medical Technology Holdings reported an operating loss of approximately $5.7 million for the year ended December 31, 2024, compared to a loss of approximately $5.6 million for the year ended December 31, 2023.
• Revenues generated from sales of CaverStem kits were $11,000 and $9,000 for the years ended December 31, 2024, and December 31, 2023, respectively.
• Research and development expenses for the year ended December 31, 2024, totaled $2,400,777, compared to $1,970,639 for the year ended December 31, 2023.
• The company had cash and short-term U.S. treasuries of approximately $5.9 million as of December 31, 2024.
• The company completed a registered direct offering and concurrent private placement in October 2024, raising approximately $1.6 million in net proceeds.
• The company is advancing clinical trials for Type I Diabetes (CELZ-201 CREATE-1) and AlloStemSpine Chronic Lower Back Pain (CELZ-201 ADAPT).
• The company received Orphan Drug Designation (ODD) from the FDA for the treatment of Brittle Type 1 Diabetes using its ImmCelz (CELZ-100) platform in March 2024.
• The company initiated a program to diagnose and treat patients exposed to biological and chemical weapons by combining artificial intelligence (AI) with its proprietary iPSC in July 2024.
• The first cohort of the CELZ-201 ADAPT clinical trial completed the study phase without any dose-limiting toxicities or serious adverse events in January 2025.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments in clinical trials and FDA designations, the company continues to operate at a loss and will need to raise additional capital. The sentiment is neutral as the company is making progress but still faces financial challenges.

Positives

• The company received Orphan Drug Designation (ODD) from the FDA for the treatment of Brittle Type 1 Diabetes using its ImmCelz (CELZ-100) platform.
• The company initiated a program to diagnose and treat patients exposed to biological and chemical weapons by combining artificial intelligence (AI) with its proprietary iPSC.
• The first cohort of the CELZ-201 ADAPT clinical trial completed the study phase without any dose-limiting toxicities or serious adverse events.
• The DSMB approved continuation of the AlloStemSpine study, validating the safety and integrity of the trial design.

Negatives

• The company incurred an operating loss of approximately $5.7 million for the year ended December 31, 2024.
• Revenues generated from sales of CaverStem kits were only $11,000 for the year ended December 31, 2024.
• The company has a history of losses and its future profitability is uncertain.

Risks

• The company's future profitability is uncertain.
• The company will need additional capital to fund its operations.
• The company's product candidates commercial viability remains subject to current and future preclinical studies, clinical trials, and regulatory approvals.
• The company may not be successful in its commercialization efforts for its proposed products and therapies.
• The company relies in part on third parties for research and clinical trials for its products and therapies.
• The company is subject to risks arising from the global outbreak of the COVID-19 coronavirus.
• The company is subject to risks arising from the wars in Ukraine and the Gaza Strip.

Future Outlook

The company believes it will have sufficient cash to meet its anticipated operating costs and capital expenditure requirements through at least March 2026 and anticipates that it will need to raise additional capital in the future to support its ongoing operations and continue its clinical trials.

Management Comments

• Management is currently re-evaluating the marketing strategy for the Caverstem and FemCelz products.
• Management believes that this space is adequate to meet our current and foreseeable needs.

Industry Context

The company competes with many pharmaceutical, biotechnology and medical device companies, as well as other private and public stem cell companies involved in the development and commercialization of cell-based medical technologies and therapies.

Comparison to Industry Standards

• Companies working in the area of regenerative medicine with regard to the disc and spine include, among others, Mesoblast, Longeveron, BioRestorative Therapies, and DiscGenics.
• Recent U.S. clinical trials using stem cells administered directly into the disc have shown promise in regenerating injured discs, and by this means reducing pain in some patients.
• Companies such as Mesoblast Limited have patient follow-ups as long as three years post injection and show some degree of pain reduction and disc regeneration without adverse effects.

Related Party Transactions

• The company acquired a patent from CMH, a related company, on February 2, 2016, in exchange for 43,112 shares of CMTH restricted common stock valued at $100,000.
• The company, through its subsidiary StemSpine, LLC, acquired a patent from CMH, a related company, on May 17, 2017, covering the use of various stem cells for the treatment of lower back pain from pursuant to a Patent Purchase Agreement, which was amended in November 2017.
• On December 28, 2020, ImmCelz, Inc. (ImmCelz), a newly formed Nevada corporation and wholly owned subsidiary of the Company, entered into a Patent License Agreement dated December 28, 2020 (the Agreement), with Jadi Cell, LLC. (Jadi), a company controlled by Dr. Amit Patel, a former director of the Company.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees' job security is dependent on the company's ability to secure funding and achieve profitability.
• Patients may benefit from the company's development of new therapies, but face risks associated with clinical trials.
• Suppliers and creditors face risks associated with the company's financial instability.

Next Steps

• Enroll the second cohort in the AlloStemSpine trial in the first quarter of 2025.
• Comprehensive data from subsequent cohorts guiding future clinical and regulatory plans.

Key Dates